This is a preview of subscription content, log in via an institution to check access.
Notes
A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
The study was funded by Amgen Inc.
Reference
Graham CN, et al. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-Type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clinical Therapeutics : 13 Apr 2016. Available from: URL: http://doi.org/10.1016/j.clinthera.2016.03.023
Rights and permissions
About this article
Cite this article
Panitumumab good choice in chemotherapy-refractory CRC. PharmacoEcon Outcomes News 752, 30 (2016). https://doi.org/10.1007/s40274-016-3024-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3024-2